FDA Scrutinizes Telehealth GLP-1 Drugs | STAT News Roundup
The Food and Drug Administration is increasing its oversight of telehealth companies marketing compounded versions of glucagon-like peptide-1 (GLP-1) drugs, medications initially developed for diabetes that have gained popularity for weight loss. This increased scrutiny comes as questions arise regarding the supply chain transparency within this rapidly expanding market. A recent report indicates that the … Read more